Clinical trial
A Multicenter, Prospective, Observational Study to Evaluate the Efficacy and Safety of Long-term Administration of K-CAB Tab./K-CAB ODT 25 mg as Maintenance Therapy Following the Treatment of GERD
NCT07920679 is registered in ClinicalTrials.gov with HK inno.N Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Observational Study to Evaluate the Efficacy and Safety of Long-term Administration of K-CAB Tab./K-CAB ODT 25 mg as Maintenance Therapy Following the Treatment of GERD
- Lead sponsor
- HK inno.N Corporation
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- August 14, 2025
- Completion date
- June 30, 2030
- Enrollment
- 12,868 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
maintenance therapy following treatment for gastroesophageal reflux disease(gerd)
Primary endpoints
Registered primary outcome measures; 1 primary.
-
The proportion of study participants with a Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) score below 8 at Week 24 after administration of K-CAB Tab/K-CAB ODT 25 mg
A GerdQ score below 8 is defined as no recurrence of GERD
Lead sponsor's other trials
HK inno.N Corporation, most recent start first.
+98 more trials See the organization page
Similar trials
Same condition (Gastroesophageal Reflux) and phase, most recent start first.
+345 more trials See the condition page